Lifecore Biomedical, Inc. (LFCR): Shareholders' Equity
$1.34M
As of 2025-05-25
-$34.09M
As of 2026-06-30
-75.2%
3-year compound annual growth
-64.3%
5-year compound annual growth
-39.9%
10-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-05-25 | $1.34M | -88.2% | 2025-08-07, Balance as of period end |
| 2024-05-26 | $11.31M | n/m | 2025-08-07, Balance as of period end |
| 2023-05-28 | -$4.23M | n/a | 2024-08-26, Balance as of period end |
| 2023-02-26 | $35.02M | n/a | 2024-03-20, Balance as of period end |
| 2022-11-27 | $71.14M | n/a | 2024-03-20, Balance as of period end |
| 2022-08-28 | $77.88M | n/a | 2024-03-20, Balance as of period end |
| 2022-05-29 | $87.82M | n/a | 2024-08-26, Balance as of period end |
| 2022-02-27 | $142.56M | n/a | 2024-03-20, Balance as of period end |
| 2021-11-28 | $155.42M | n/a | 2024-03-20, Balance as of period end |
| 2021-08-29 | $193.12M | n/a | 2024-03-20, Balance as of period end |
| 2021-05-30 | $201.95M | n/a | 2024-03-20, Balance as of period end |
| 2021-02-28 | $202.20M | n/a | 2024-03-20, Balance as of period end |
| 2020-11-29 | $208.00M | n/a | 2024-03-20, Balance as of period end |
| 2020-08-30 | $218.54M | n/a | 2024-03-20, Balance as of period end |
| 2020-05-31 | $231.04M | -14.5% | 2023-03-16, Balance as of period end |
| 2019-05-26 | $270.14M | +7.0% | 2021-07-29, Balance as of period end |
| 2018-05-27 | $252.56M | +11.5% | 2019-08-01, Balance as of period end |
| 2017-05-28 | $226.61M | +7.5% | 2018-08-09, Balance as of period end |
| 2016-05-29 | $210.73M | -3.5% | 2018-03-15, Balance as of period end |
| 2015-05-31 | $218.43M | +7.6% | 2016-08-01, Balance as of period end |
| 2014-05-25 | $203.07M | +13.6% | 2015-07-31, Balance as of period end |
| 2013-05-26 | $178.69M | +19.3% | 2014-08-01, Balance as of period end |
| 2012-05-27 | $149.74M | +10.1% | 2013-08-07, Balance as of period end |
| 2011-05-29 | $136.06M | n/a | 2012-08-08, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | $1.34M | -88.2% |
| Xencor Inc (XNCR) | 2025-12-31 | $635.59M | -6.2% |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $106.03M | +67.5% |
| Karyopharm Therapeutics Inc. (KPTI) | 2025-12-31 | -$292.93M | n/m |
| Elite Pharmaceuticals Inc (ELTP) | 2026-03-31 | $98.88M | +84.8% |
| Macrogenics Inc (MGNX) | 2025-12-31 | $55.59M | -52.1% |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | -$105.47M | n/m |
| Theravance Biopharma, Inc. (TBPH) | 2025-12-31 | $296.72M | +69.0% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $14.33M | n/m |
Compare LFCR, XNCR, GYRE, KPTI side by side · Screen every company in Pharmaceutical Preparations ↗